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Abstract
Background: Glucocorticoid hormones play a major role in fetal organ maturation. Yet, excessive glucocorticoid exposure in
utero can result in a variety of detrimental effects, such as growth retardation and increased susceptibility to the
development of hypertension. To protect the fetus, maternal glucocorticoids are metabolized into inactive compounds by
placental 11beta-hydroxysteroid dehydrogenase type2 (11bHSD2). This enzyme is also expressed in the kidney, where it
prevents illicit occupation of the mineralocorticoid receptor by glucocorticoids. We investigated the role of renal 11bHSD2
in the control of neonatal glucocorticoid metabolism in the human and mouse.
Methods: Cortisol (F) and cortisone (E) concentrations were measured in maternal plasma, umbilical cord blood and human
newborn urine using HPLC. 11bHSD2 activity was indirectly assessed by comparing the F/E ratio between maternal and
neonatal plasma (placental activity) and between plasma and urine in newborns (renal activity). Direct measurement of
renal 11bHSD2 activity was subsequently evaluated in mice at various developmental stages. Renal 11bHSD2 mRNA and
protein expression were analyzed by quantitative RT-PCR and immunohistochemistry during the perinatal period in both
species.
Results: We demonstrate that, at variance with placental 11bHSD2 activity, renal 11bHSD2 activity is weak in newborn
human and mouse and correlates with low renal mRNA levels and absence of detectable 11bHSD2 protein.
Conclusions: We provide evidence for a weak or absent expression of neonatal renal 11bHSD2 that is conserved among
species. This temporal and tissue-specific 11bHSD2 expression could represent a physiological window for glucocorticoid
action yet may constitute an important predictive factor for adverse outcomes of glucocorticoid excess through fetal
programming.
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Introduction
Glucocorticoid hormones play a critical role in promoting
maturation of fetal organs essential for neonatal adaptation to
extrauterine terrestrial life. Numerous studies have underlined the
importance of glucocorticoids in fetal lung development. It is well
established that antenatal administration of corticosteroids in women
at risk of preterm delivery prevents neonatal respiratory distress
syndrome [1]. Moreover, via the activation of the glucocorticoid
receptor (GR), a transcription factor, glucocorticoids are able to
stimulate the expression and activation of the epithelial sodium
channel in lungs [2], crucial for pulmonary fluid resorption at birth
[3].However,excessive glucocorticoidexposureinuterohas numerous
harmful effects. It reduces fetal growth [4] and is associated with
increased susceptibility to the development of hypertension [5–7],
glucoseintolerance [8] and anxiety related disorders inadulthood [9].
These deleterious effects have been related to epigenetic modifica-
tions during fetal programming [10,11].
Transfer of maternal glucocorticoids to the fetus is controlled
mainly by a placental functional barrier : the enzyme 11-beta-
hydroxysteroid dehydrogenase type 2 (11bHSD2). This enzyme
metabolizes active glucocorticoids into inactive 11-keto com-
pounds i.e cortisol (F) into cortisone (E) in humans or
corticosterone (B) into 11-dehydrocorticosterone (A) in rodents,
while it has almost no effect on the metabolism of synthetic
glucocorticoids (betamethasone and dexamethasone) or aldoste-
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powerful in the placenta and increases during gestation [13],
protecting the fetus from excessive impregnation by maternal
glucocorticoids. Indeed, reduced placental 11bHSD2 activity has
been associated in humans and mice with intra-uterine growth
retardation [13,14], and preeclampsia [15,16].
11bHSD2 is also expressed by various organs aside from the
placenta. Particularly, it has been shown to colocalize with the
mineralocorticoid receptor (MR) in aldosterone-sensitive epithelial
tissues [17,18] where it is a key element of mineralocorticoid
selectivity [19] protecting MR from illicit occupancy and
activation by overwhelming cortisol concentrations [20–23].
Many studies have focused on placental 11bHSD2 activity, but
little is known about its expression and function in the neonatal
kidney. Significant levels of 11bHSD2 mRNA have been detected
in mouse embryonic kidneys at various developmental stages
associated with a decrease of mRNA expression near term, by in
situ hybridization or northern blot analyses [24–26]. Similar results
have been found in human fetal kidneys with an onset of
11bHSD2 expression early during gestation [17,27]. However,
11bHSD2 renal protein expression and activity at birth have never
been reported. The phenotype observed in 11bHSD2 knock-out
newborn mice could be related to the lack of placental expression
as well as to the absence of renal expression. The susceptibility to
hypertension after fetal exposure to high levels of glucocorticoids
could also be related to direct renal effects of glucocorticoids [11].
We have previously demonstrated that both mouse and human
newborns have very low renal MR expression at birth [28].
Therefore, we hypothesize that the 11bHSD2 enzyme is either
absent or below detectable threshold in the newborn kidney, since
MR protection is not required. In order to verify this hypothesis,
we measured cortisol (F compound) and cortisone (E compound)
concentrations in maternal plasma, umbilical cord blood and in
human newborn urine. We report the first evaluation of renal
neonatal 11bHSD2 activity, by comparing the F/E ratio between
plasma and urine in human newborns. Subsequently, we assessed
11bHSD2 activity at various developmental stages in mouse
kidneys. We have also analyzed renal 11bHSD2 mRNA and
protein expression during gestation, in both species, using
quantitative RT-PCR and immunohistochemistry, which has not
been reported to date. Our results demonstrate a lack of renal
11bHSD2 enzymatic activity at birth, related to a low renal
expression, which parallels the relatively low fetal plasma cortisol
levels measured in human newborns.
Materials and Methods
Patients
Patients have been previously described [29]. In brief, 44 healthy
mother-neonate couples were included in the study. Singleton
pregnancies were uncomplicated, and led to the birth of full-term
healthy eutocic newborns, which were enrolled in the study.
Informed and written consents were obtained for all patients.
Written parental consent was obtained for all newborn testing. The
study was approved by the local ethical committee (CCPPRB :
Comite ´ Consultatif Pour les Personnes en Recherche Biome ´dicale,
Ho ˆpital Antoine-Be ´cle `re, Clamart, France), and was conducted in
regardstotheDeclarationofHelsinki’sguidelines.Plasmaandurine
were collected from fifty healthy female adults, after obtention of
informed and written consents, and used as controls.
Plasma and urinary samples
Collection and conservation of maternal plasma samples and
neonatal plasma and urine samples have been described previously
[29]. Maternal blood samples were collected just before delivery,
during preanalgesia peridural checkup. Neonatal blood samples
were obtained from umbilical cord vein at birth. Single-spot
urinary samples were collected on the day of birth from a gauze
compress settled in the newborns diapers. This simple, non
invasive, original method has already proven its efficacy for the
measurement of aldosterone concentrations [29]. We did not
perform 24-hours urinary collection in newborns for evident
ethical reasons.
Hormonal and biochemical analyses
Simultaneous determination of cortisol and cortisone was
conducted by using a high performance liquid chromatography
of maternal plasma, umbilical cord blood and urine samples as
previously described [30]. For blood samples, steroids were
extracted from plasma with dichloromethane. For urine analysis,
steroids were extracted with dichloromethane and purified on
accubond II Octyl cardridges 100 mg (Agilent Technologie,
Interchim, Montluc ¸on, France). 6a-methylprednisone was used
as an internal standard. After evaporation, the residue was
reconstituted in mobile phase for HPLC injection. The Waters
HPLC system (515 pump, Wisp 717 plus autosampler and a UV
486 absorbance detector at 254 nm) was equipped with a
Symmetry Shield 5 mm C8 reverse phase column (Waters, Saint
Quentin, France). The mobile phase was a 55% methanol in water
solution at a flow rate of 0.8 ml/min. The detection limit for both
steroids was 1–2 ng/ml and the intra- and inter-day assay
variations were less than 10%. Extraction recoveries of both
steroids were more than 90% in plasma and 70% in urine. The
detection was linear over the range of 10 to 1000 ng/ml. Urinary
creatinine concentrations were measured with automat Modular
P900 using a rate-blanked Jaffe ´ based method (Roche Diagnostics,
France). Urinary cortisol and cortisone concentrations were
normalized by urinary creatinine levels.
Mouse kidney samples
Mice were cared according to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996). The animal
facility was granted approval (Nu B94-043-12), with an authoriza-
tion to experiment on living animals (75–978, ML) given by the
French Administration (Prefecture du Val de Marne, Direction
de ´partementale des services ve ´te ´rinaires du Val de Marne). Wild
type mouse kidneys were collected at 17.5 days of gestation (E17.5)
(embryonicday 0.5being the day of the plug), at birth (D0.5)and on
postnatal day 8 (D8.5). Kidneys were snap-frozen in liquid nitrogen
for quantitative RT-PCR analyses. Animal experiments and
housing were conducted in accordance with the guidelines of the
animal ethics committee of the Ministe `re de l’Agriculture (France).
Human kidney samples
Snap-frozen fetal kidney samples were obtained from the
Foetopathology Department of Robert Debre Hospital. They
originated from in utero fetal deaths with rapid delivery and autopsy
within 24 to 36 hours post mortem. Nineteen samples from fetuses
aged 14–40 gestational weeks were used for qPCR quantification of
renal 11bHSD2 expression. Parental informed and written consents
were collected for all samples, after declaration of the study to the
French Biomedical Agency (Decree 003812, 09/22/2006).
Quantitative real-time RT-PCR
Two micrograms of total RNA isolated from frozen human and
mouse kidney samples were submitted to reverse-transcription,
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Quantitative PCR were subsequently performed using 100 ng
cDNA with qPCR Mastermix Plus for Sybr Green I (Eurogentec)
and 300 nM of specific 11bHSD2 primers. Oligonucleotid
sequences were as follows:
Mouse 11bHSD2 sense: 59-AACCTCTGGCAGAAACGCAAG-
39 and antisense: 59-GGCATCTACAACTGGGCTAAGG-39
Human 11bHSD2 sense: 59-CTGGACTCCATGGGCTT-
CAC-39 and antisense: 59-TGAACTCTAGCACGCGGCTAA-39
Reaction parameters were carried out on an ABI 7300
Sequence Detector (Applied Biosystems). For standards prepara-
tions, amplicons were subcloned into pGEMT-Easy plasmid
(Promega, Madison, WI). Standards were sequenced in order to
confirm their identity. Serial dilutions of the linearized plasmids
were used to generate standard curves. Standard and samples
values were determined in duplicate from at least three different
experiments. Relative expression for a given sample was expressed
as the ratio between the expression of the specific gene in
attomoles normalized by ribosomal 18S expression in femtomoles,
which was used as an internal control.
11bHSD2 assay
Mouse kidneys at different developmental stages were collected
and snap-frozen in dry-ice. Samples were homogenized and
sonicated in ice-cold 0.1 M PBS pH 7.5. After centrifugation at
10 000 g for 30 min, the resulting supernatant was assayed for
protein concentration using the BCA protein assay kit (Pierce,
Rockford, IL, USA) with BSA as a standard. C11 dehydrogenase
activity was determined by measuring the rate of conversion of
3H-
cortisol to produce
3H-cortisone as previously described [31]. Fifty
or 100 mg of protein homogenate in PBS buffer and 1 nM tritium-
labeled cortisol in methanol were incubated 120 min at 37uC with
or without addition of 1 mM NAD and 10
26 M carbenoxolone.
Steroids were extracted with ice-cold ethyl-acetate. After evapo-
ration of the organic phase, cortisol and cortisone were separated
on the HPLC system described above and monitored by an
ultraviolet absorbance detector and a Berthold LB 513 scintillation
counter to detect tritiated steroids. Calibration was carried out
with standard calibration curves of labeled cortisone. The rate of F
to E conversion was expressed as the amount of picomoles of
3H-
cortisone formed per mg protein per 2 hours.
Immunohistochemistry
Neonatal and infantile human kidneys were selected from two
pathology departments’ collections according to the guidelines of
the French Biomedical Agency. These samples originated from
sudden infant deaths. Quality and integrity of the samples were
verified by immunostaining with vimentin (as a control of
appropriate formol fixation) and a low molecular weight
cytokeratin (as a control of epithelial tubular cell integrity). Three
different antibodies were used: polyclonal antihuman 11bHSD2
(Alpha Diagnostic International, San Antonio, Texas) at 15 mg/ml
dilution, monoclonal anti-vimentin clone V9 (Biogenex Labora-
tories, San Ramon, CA) and anti-cytokeratin 19 antibodies
(Progen, Queensland, Australia), at dilutions of 1:100 and 1:120
respectively. Immunohistochemistry was conducted as previously
described [28]. Briefly, after paraffin removal, and antigen
retrieval in Tris-EDTA pH 9 buffer at 85uC in a hot water bath
for 2 h (for 11bHSD2) or in citrate buffer pH 6 in a microwave
oven for 15 min (for vimentin and cytokeratin), slides were
incubated overnight at 4uC with the appropriately diluted primary
antibody or control immunoglobulins (rabbit and mouse IgG and
control ascite fluid (Sigma)). Bound immunoglobulins were then
revealed with a biotin-free immunostaining Kit (Immpress Reagent
kit, Vector, Burlingame, California). Aminoethylcarbazol (DAKO,
San Antonio, Texas) was used as a chromogen.
Statistical analyses
Data are expressed as mean 6 SEM. For qPCR analyses of
11bHSD2 expression in mouse kidneys, six samples from at least
six different mice were used for each developmental stage. For
human samples, results represent the mean of at least three
independent experiments of three different reverse- transcribed
samples, normalized using an internal calibrator. For 11bHSD2
assay, results represent the mean of three independent experiments
for each developemental stage and each condition. Statistical
analyses were performed using computer software Prism 4
(GraphPad Software, San Diego, CA). Non parametric Mann-
Whitney tests or unpaired t-tests were used to compare two
parameters. Significant threshold was determined at 0.05.
Results
Forty-four mother-neonate couples were included in the study.
Forty-three maternal blood samples and 44 umbilical cord blood
samples were obtained and analyzed for plasma cortisol (F) and
cortisone (E) levels. Urinary samples were collected from fourteen
of these neonates, allowing quantification of F and E excretion
levels at birth.
Placental 11bHSD2 is extremely active at the end of
gestation
We first compared plasma E and F levels between mothers and
their neonates (Fig. 1). As observed in Figure 1A, maternal plasma
F levels are significantly higher than neonatal levels (630651 vs
7566 ng/ml, respectively, p,0.0001). Conversely, cortisone levels
are significantly lower in mothers than in their newborns (12367
vs 260614 ng/ml respectively, p,0.0001). This maternal-fetal
gradient indicates that cortisol, present in high concentrations in
maternal plasma, does not freely cross the placental barrier
without metabolic conversion. Indeed, when we compared F/E
ratio in both maternal and umbilical cord blood, we found a
striking difference with a higher ratio in mothers than in newborns
(5.260.30 vs 0.360.02, p,0.0001) in which E concentrations
largely excedeed that of F (Fig. 1B). These results suggest that
maternal cortisol is metabolized into cortisone by the placenta,
afterwhich cortisone crosses the placental barrier into the fetal
circulation. This could explain why high levels of cortisone are
detected in newborns plasma. These results reflect the strong
enzymatic activity of placental 11bHSD2, which persists in late
gestation.
Weak activity of renal 11bHSD2 in newborns
As demonstrated in Figure 1B, plasma F levels are lower than E
levels (p,0.0001) in newborns. These low levels of plasma cortisol
may reflect the fetal adrenal biosynthesis [32]. High cortisone
levels could either come from the mother via the placenta or from
active cortisol metabolism by fetal 11bHSD2. To address this
issue, we measured F and E concentrations in newborn urine
collected onto a gauze compress (Fig. 2). This simple, non invasive
method, suitable for steroid assessment [29], allowed us to obtain
between 200 ml and 5 ml of urine. This is the first determination of
urinary E and F concentrations at birth. Mean urinary F value was
7566 ng/mg creatinine with median at 71 ng/mg creatinine.
Mean urinary E value was 258614 ng/mg creatinine with median
at 225 ng/mg creatinine (Fig. 2A). Levels of urinary E were found
significantly higher than those of urinary F (p,0.0001), which is
normally expected and could reflect the activity of the renal
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plasmatic and urinary F/E ratios of these neonates (Fig. 2B).
Surprisingly, similar ratios were observed in these two compart-
ments (0.3160.02 vs 0.3260.06, p=0.95). In contrast, there was a
strinking difference between the plasma and urinary F/E ratios in
50 healthy control adults (3.660.17 vs 0.360.01), demonstrating
strong activity of renal 11bHSD2 in mature kidneys. These results
therefore suggest that, at variance with adults, renal 11bHSD2
activity is very low in human newborns.
11bHSD2 mRNA expression and activity during mouse
renal development
We have previously demonstrated that the mineralocorticoid
signaling pathway follows a similar expression pattern both in mice
and human, with a low MR mRNA and protein expression at
birth and a postnatal up-regulation in both species [28]. Based on
the MR expression profile, we wondered if this low renal
11bHSD2 activity in human newborns was conserved in the
mouse. To further explore this hypothesis and investigate the
underlying mechanisms, we quantified 11bHSD2 renal mRNA
levels using quantitative RT-PCR and measured enzymatic
activity by evaluating the rate of conversion of
3H-cortisol to
3H-cortisone throughout mice renal development. Renal organ-
ogenesis in the mouse starts at E8 and ends postnatally at D8. We
have previously demonstrated that renal MR expression peaks at
E17.5, is low at birth, and increases to reach a steady state at D8 in
the postnatal period, while GR renal expression stays high
throughout the perinatal period [28]. 11bHSD2 mRNA levels
and enzymatic activity were therefore quantified at three
developmental stages in the mouse : E17.5, D0.5 and D8.5, and
in adult mice (Fig. 3A and 3B). We demonstrate that, mirroring
MR, 11bHSD2 mRNA expression is low during gestation and
especially at birth (0.12 amol/fmol 18S), before increasing
significantly by 2-fold in the postnatal period, following kidney
maturation (Fig. 3A). Interestingly, 11bHSD2 enzymatic activity
correlated with mRNA expression with no detectable activity at
birth, followed by a drastic postnatal increase (Fig. 3B). This
enzymatic activity is specifically NAD-dependant and is inhibited
by carbenoxolone.
These results therefore reveal that, as in humans, renal
11bHSD2 activity is very weak or undetectable in newborn mice,
owing to a low 11bHSD2 mRNA expression at birth.
11bHSD2 mRNA and protein expression during human
renal development
To further investigate the possible underlying mechanisms of low
renal 11bHSD2 activity in human newborns, we quantified mRNA
levels by qPCR throughout gestation in 19 human kidney samples
collected from fetuses aged 14 to 40 gestational weeks [33], and
analyzed protein expression using immunohistochemistry in kidney
samples from a newborn and a one year old infant (Fig. 4). Human
renal organogenesis occurs between 5 and 36 GW, but human
kidneys only reach full maturation at the end of the first year of life
[28,34]. We found that 11bHSD2 mRNA expression increases
progressively and significantly (p,0.0001) throughout gestation
(Fig. 4A), paralleling renal maturation and that this progression is
likely to continue in the postnatal period. This was also observed in
the mouse, with lower renal mRNA levels at birth than during the
postnatal period. Indeed, no 11bHSD2 protein is detectable by
immunohistochemistry in newborn kidney, whereas a specific
immunolabeling is observed at one year of age in renal cortical
collecting duct epithelium (Fig. 4B).
In summary, all results concur to demonstrate a very weak or
absent renal 11bHSD2 enzymatic activity at birth, in relation to a
low mRNA and protein expression, both in mice and humans.
Discussion
This study represents the first demonstration of a weak or absent
11bHSD2 activity in the human newborn kidney. In human
neonates, the ratio cortisol/cortisone reflecting the dynamics of the
enzymatic conversion of glucocorticoids by 11bHSD enzymes is
strictly identical between newborn plasma and urine, whereas in
Figure 1. Plasma cortisol (F) and cortisone (E) levels, and F/E ratio in mothers and their neonates. A: Comparison of plasma cortisol and
cortisone levels between mothers and neonates. Results for each parameter are expressed in ng/ml, as means 6 SEM of the 43 values obtained from
the mother-neonate couples. Plasma cortisol levels are significantly higher in mother than in neonates (*** p,0.001), and on the contrary, plasma
cortisone levels are significantly lower (*** p,0.001). B: Comparison of the F/E ratio between maternal and neonatal plasma. The F/E ratio, which
corresponds to cortisol metabolism by the 11bHSD2 enzyme, is significantly higher in mothers than in neonates (*** p,0.001). These results reflect a
strong activity of the placental 11bHSD2.
doi:10.1371/journal.pone.0031949.g001
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emphasizing the strong activity of adult renal 11bHSD2. The
conversion of cortisone to cortisol by 11-beta-hydroxysteroid
dehydrogenase type 1 (11bHSD1) mainly occurs in the liver and is
almost undetectable in the kidney in both mouse and human
[25,26,35]. Thus, the steady state of F/E ratio between plasma
and urine in human newborns relies rather on the absence of renal
11bHSD2 activity than on an equilibrium between renal
11bHSD2 and 11bHSD1 activities. This observation has been
confirmed by direct measurement of 11bHSD2 activity in mouse
kidney at various developmental stages. The enzymatic activity is
very low in the prenatal and neonatal period and increases
drastically postnatally. We have demonstrated that this weak
activity is related to a low renal 11bHSD2 mRNA expression at
birth both in mice and human which is concomitant with the
absence of detectable protein in human kidney. Interestingly,
others have demonstrated a specific 11bHSD2 expression in the
fetal kidney both in mice [24–26] and human [17,27] that
contrasts with a low fetal enzymatic activity as demonstrated at
E17.5 in our study and at E15 in [26], and could result from
protein instability [36].
Therefore, renal 11bHSD2 follows a triphasic temporal
expression profile, conserved among species that is reminiscent
of that of the renal expression profile of other actors of the
mineralocorticoid signaling pathway: the mineralocorticoid recep-
tor and the alpha-subunit of the epithelial sodium channel
(aENaC) [28], with a peak of expression during fetal life, a
specific downregulation in the neonatal period and an up-
regulation in the postnatal period. It could thus be hypothesized
that all these molecular signaling partners follow a parallel
maturation profile throughout renal development. On the other
hand, is ensuring MR protection the only role of renal 11bHSD2 ?
Moreover, could the absence of expression and activity of the
enzyme in neonatal kidneys be particularly relevant during this
specific developmental stage?
The weak renal 11bHSD2 activity contrasts with the strong
placental enzymatic activity persistent in the prenatal period. An
increased 11bHSD2 expression has been previously described in
human placenta during the last trimester, associated with a
decreasing F/E ratio in the amniotic fluid [37]. This heightened
activity is necessary to protect the fetus from excessive glucocor-
ticoid hormone exposure. Indeed, lack of placental 11bHSD2
activity leads to fetal and neonatal complications similar to those of
glucocorticoid overexposure : reduced fetal growth [38] and
susceptibility to development of hypertension and metabolic
syndrome [7]. Human placental 11bHSD2 expression has been
Figure 2. Urinary cortisol (F) and cortisone (E) concentrations and F/E ratio, in full-term newborns. A: Comparison between F and E in
neonatal urine. Results are expressed in ng/mg of urinary creatinine concentration, as means 6 sem of the 44 values obtained in neonates. Cortisol
levels are significantly lower than cortisone levels (*** p,0.001). B: Comparison between plasma and urinary F/E ratio in neonates and in 50 healthy
control adults. No difference was observed between the F/E ratio in plasma and urine at birth, which could reflect an inactivity of the neonatal renal
11bHSD2. On the contrary this enzyme is very active in adults, with an inversion of the F/E ratio in urine, significantly different from the plasma ratio
(*** p,0.001).
doi:10.1371/journal.pone.0031949.g002
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represents an important safeguard mechanism [39]. Circulating
cortisol levels at birth originate most notably from fetal adrenal
biosynthesis as early as the second trimester of gestation [40] and/
or the rise in 11beta-hydroxysteroid dehydrogenase type 1
expression in human fetal membranes near term [41,42].
However, these concentrations are low and might therefore not
be adequate for optimal and sustained stimulation of renal
11bHSD2 expression. Yet, they are sufficient to fully occupy the
GR and activate the glucocorticoid signaling pathway [43].
Moreover, we have previously demonstrated that GR is expressed
in the kidney at birth both at the mRNA and protein levels [28].
GR is detected in the nuclei of the cortical collecting duct cells,
suggesting ligand-mediated activation of this receptor and
functionality of the glucocorticoid signaling pathway. We could
then wonder why the major regulator of glucocorticoid metabo-
lism, 11bHSD2, is not expressed? Could this lack of expression
represent a temporal window necessary for glucocorticoid activity?
The combined lack of renal 11bHSD2 activity and the absence of
MR expression in the neonatal kidney leave glucocorticoids free to
access and activate GR, which might have an important role in
kidney development and maturation. It has been suggested that
glucocorticoids are implicated in developmental programming
[10,11]. This hypothesis could be sustained by the fact that, at
variance with the kidney, 11bHSD2 activity is detected in other
organs in the newborn. It is particularly interesting to note that
while it is barely expressed in the adult brain, a high 11bHSD2
activity is detected in the developping central nervous system in
rats, mice and humans until the end of gestation [24,44]. It has
been postulated that 11bHSD2 during fetal and neonatal life is
essential to protect the developing nervous system from deleterious
consequences of glucocorticoid exposure [45]. Therefore
11bHSD2 could have an organ specific pattern of expression in
the neonatal period, protecting against or facilitating glucocorti-
coid actions. This developmental process could contribute to the
increased short-term adverse outcome rate observed in extremely
low birth weight infants with high cortisol concentrations [46].
Moreover, this specific temporal window where the kidney
appears to be particularly sensitive to glucocorticoid action could
explain the deleterious effects of prenatal glucocorticoid overex-
posure on renal development [47,48] or epigenetic modifications
leading to the predisposition for adult hypertension [11,49,50].
Finally, our study demonstrates the existence of a physiological,
temporal 11bHSD2 expression window specific to the kidney,
which appears to be necessary for optimal fetal and neonatal
development, but as a result could also represent a breach in the
protective mechanisms against excess glucocorticoid exposure
responsible for adverse short-term and long-term effects through
Figure 3. 11bHSD2 mRNA expression and activity throughout renal development in mice. A: Relative mRNA expression in mice was
determined using qPCR at various developmental stages, as follows : E 17.5, D 0.5 and D 8.5 E: Embryonic day, D: Postnatal day. Results, expressed as
the ratio of attomoles of specific gene per femtomole of ribosomal 18S, correspond to mean 6 SEM (E17.5 n=9, D0.5 n=17, D8.5 n=6). *** p,0.001.
B: Renal 11bHSD2 activity was determined at the same developmental stages and in adults, by measuring the rate of conversion of
3H-cortisol into
3H-cortisone, under three conditions : basal, with NicotinAmid Dinucleotid (NAD), with NAD and carbenoxolone, a specific 11bHSD2 inhibitor. Results,
expressed as the ratio of picomoles of enzymatic activity after 2 hours per micrograms of protein, represent the mean 6 SEM of three independent
experiments for each developmental stage and each condition. * p,0.05; ** p,0.01, NS : Not Significant.
doi:10.1371/journal.pone.0031949.g003
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